Mostrar el registro sencillo del ítem

dc.contributor.authorPérez Castrillon, José Luis 
dc.date.accessioned2024-01-17T19:13:33Z
dc.date.available2024-01-17T19:13:33Z
dc.date.issued2021
dc.identifier.citationJournal Bone and Mineral Research 2021; 36 ( October ): 1967-1978es
dc.identifier.issn0884-0431es
dc.identifier.urihttps://uvadoc.uva.es/handle/10324/64702
dc.descriptionProducción Científicaes
dc.description.abstractABSTRACT Vitamin D has shown to play a role in multiple diseases due to its skeletal and extraskeletal actions. Furthermore, vitamin D deficiency has become a worldwide health issue. Few supplementation guidelines mention calcifediol treatment, despite being the direct precursor of calcitriol and the biomarker of vitamin D status. This 1-year, phase III–IV, double-blind, randomized, controlled, multicenter clinical trial assessed the efficacy and safety of calcifediol 0.266 mg soft capsules in vitamin D–deficient postmenopausal women, compared to cholecalciferol. Results reported here are from a prespecified interim analysis, for the evaluation of the study’s primary endpoint: the percentage of patients with serum 25-hydroxyvitamin D (25(OH)D) levels above 30 ng/ml after 4 months. A total of 303 patients were enrolled, of whom 298 were included in the intention-to-treat (ITT) population. Patients with baseline levels of serum 25(OH)D <20 ng/ml were randomized 1:1:1 to calcifediol 0.266 mg/month for 12 months, calcifediol 0.266 mg/month for 4 months followed by placebo for 8 months, and cholecalciferol 25,000 IU/month for 12 months. At month 4, 35.0% of postmenopausal women treated with calcifediol and 8.2% of those treated with cholecalciferol reached serum 25(OH)D levels above 30 ng/ml (p < 0.0001). The most remarkable difference between both drugs in terms of mean change in serum 25(OH)D levels was observed after the first month of treatment (mean   standard deviation change = 9.7   6.7 and 5.1   3.5 ng/ml in patients treated with calcifediol and cholecalciferol, respectively). No relevant treatment-related safety issues were reported in any of the groups studied.These results thus confirm that calcifediol is effective, faster, and more potent than cholecalciferol in raising serum 25(OH)D levels and is a valuable option for the treatment of vitamin D deficiencyes
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherWileyes
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.subjectEndocrinologia y Metabolismoes
dc.subject.classificationCALCIFEDIOL; CHOLECALCIFEROL; VITAMIN D DEFICIENCY; MENOPAUSE; CLINICAL TRIALSes
dc.titleCalcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized triales
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.doiDOI: 10.1002/jbmr.4387es
dc.identifier.publicationfirstpage1967es
dc.identifier.publicationissue10es
dc.identifier.publicationlastpage1978es
dc.identifier.publicationtitleJournal of Bone and Mineral Researches
dc.identifier.publicationvolume36es
dc.peerreviewedSIes
dc.description.projectFaes-Farmaes
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem